Citation Impact
Citing Papers
Genetically Determined Susceptibility to Tuberculosis in Mice Causally Involves Accelerated and Enhanced Recruitment of Granulocytes
2006
Design, synthesis and biological evaluation of 6-deoxy O-spiroketal C-arylglucosides as novel renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes
2019
The modification of natural products for medical use
2016
Combination of Empagliflozin and Linagliptin as Second-Line Therapy in Subjects With Type 2 Diabetes Inadequately Controlled on Metformin
2015
Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock
2004 Standout
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
2016 Standout
Selective activation of STAT3 in human monocytes stimulated by G-CSF: implication in inhibition of LPS-induced TNF-α production
2004
Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin
2000 StandoutNature
Innate immune sensing and its roots: the story of endotoxin
2003 StandoutNobel
Immunotherapy of sepsis
2001
Melioidosis
2018 Standout
ICOS co-stimulatory receptor is essential for T-cell activation and function
2001 StandoutNatureNobel
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
2018 Standout
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
2016 Standout
Postprandial Hypoglycemia in Patients after Gastric Bypass Surgery Is Mediated by Glucose-Induced IL-1β
2020
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial
2014
Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions
2014 Standout
Targeting Amyloidogenic Processing of APP in Alzheimer’s Disease
2020
Melioidosis
2012 Standout
The changing landscape of atherosclerosis
2021 StandoutNature
Melioidosis: insights into the pathogenicity of Burkholderia pseudomallei
2006 Standout
Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial
2013
SGLT inhibitors in management of diabetes
2013
Sodium–glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy
2014
Clinical Pharmacokinetic, Pharmacodynamic, and Drug–Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor
2015
Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)
2014
Non-alcoholic fatty liver disease
2021 Standout
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
2017 Standout
Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus
2014
Type 2 diabetes
2017 Standout
Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
2014
What is the rationale for the use of granulocyte and granulocyte‐macrophage colony‐stimulating factors in the neonatal intensive care unit
2002
The preterm parturition syndrome
2006 Standout
Effect of filgrastim treatment on inflammatory cytokines and lymphocyte functions*1
1999
Type 2 diabetes mellitus
2015 Standout
Pharmacokinetic and Pharmacodynamic Profile of Empagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor
2014
G-CSF immunotherapy for treatment of acute disseminated murine melioidosis
2003
Neutrophil–Kupffer-cell interaction in host defenses to systemic infections
1998
Signal Transducer and Activator of Transcription‐3, Inflammation, and Cancer
2009 Standout
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
2015 Standout
Inflammation in obesity, diabetes, and related disorders
2022 Standout
The immunopathogenesis of sepsis
2002 StandoutNature
Interleukin-13 Effectively Down-regulates the Monocyte Inflammatory Potential During Traumatic Stress
1995
Animal models of acute lung injury
2008 Standout
Local Inflammatory Responses following Bronchial Endotoxin Instillation in Humans
2001
Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes
2015
2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association
2021 Standout
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
2023 Standout
Comprehensive Review on Alzheimer’s Disease: Causes and Treatment
2020 Standout
SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice
2013
Chronic Kidney Disease Diagnosis and Management
2019 Standout
Melioidosis: Epidemiology, Pathophysiology, and Management
2005 Standout
Pathogen Recognition and Inflammatory Signaling in Innate Immune Defenses
2009 Standout
Titan's bright spots: Multiband spectroscopic measurement of surface diversity and hazes
2006 StandoutNobel
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
2014 Standout
Precise laser frequency scanning using frequency-synthesized optical frequency sidebands: application to isotope shifts and hyperfine structure of mercury
1989 StandoutNobel
Controlled stimulated Raman amplification and oscillation in hydrogen gas
1967 StandoutNobel
Hyperfine Structures of Some Hg I Lines*
1960
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019
2020 Standout
Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock
2004 Standout
cGMP-Mediated Inhibition of TNF-α Production by the Atrial Natriuretic Peptide in Murine Macrophages
2000
Phosphine Organocatalysis
2018 Standout
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
2018 Standout
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Diabetic Cardiomyopathy
2018 Standout
Natriuretic Peptides, Their Receptors, and Cyclic Guanosine Monophosphate-Dependent Signaling Functions
2005 Standout
β-Selective C-Arylation of Silyl Protected 1,6-Anhydroglucose with Arylalanes: The Synthesis of SGLT2 Inhibitors
2015
Diabetic Kidney Disease
2017 Standout
The Immune Response in Tuberculosis
2013 Standout
Fine structure in the lines of the 2ν3 band of methane
1961
β-Selective C-Arylation of Diisobutylaluminum Hydride Modified 1,6-Anhydroglucose: Synthesis of Canagliflozin without Recourse to Conventional Protecting Groups
2015
Heterozygous Arg753Gln Polymorphism of Human TLR-2 Impairs Immune Activation by Borrelia burgdorferi and Protects from Late Stage Lyme Disease
2005
Granulocyte Colony-Stimulating Factor to Prevent the Progression of Systemic Nonresponsiveness in Systemic Inflammatory Response Syndrome and Sepsis
1999
Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 ( SGLT2 ) inhibitor, as add‐on to metformin in type 2 diabetes with mild hyperglycaemia
2013
Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes
2013
Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78‐week randomized, double‐blind, placebo‐controlled trial
2015
Plant Secondary Metabolites as Anticancer Agents: Successes in Clinical Trials and Therapeutic Application
2018 Standout
Natural Products as Sources of New Drugs from 1981 to 2014
2016 Standout
PERFORMANCE OF A VIBRATIONAL H2-STOKES OSCILLATOR
1966
Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial
2014
Granulocyte Colony-Stimulating Factor to Prevent the Progression of Systemic Nonresponsiveness in Systemic Inflammatory Response Syndrome and Sepsis
1999
Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes
2014
Dapagliflozin in Patients with Chronic Kidney Disease
2020 Standout
Empagliflozin improves glycaemic and weight control as add‐on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24‐week, randomized, placebo‐controlled trial
2013
Cell-Mediated Immune Responses in Tuberculosis
2009 Standout
Structure–Function Relationship of Cytokine Induction by Lipoteichoic Acid fromStaphylococcus aureus
2001
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
2018 Standout
Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes
2013
Empagliflozin, an SGLT2 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
2015
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension
2014
Phosphine-Triggered Tandem Annulation between Morita–Baylis–Hillman Carbonates and Dinucleophiles: Facile Syntheses of Oxazepanes, Thiazepanes, and Diazepanes
2012
Works of Achim Sauer being referenced
Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitors
2011
Long‐term treatment with empagliflozin, a novel, potent and selective SGLT‐2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats
2011
Control of Fecal Peritoneal Infection in Mice by Colony-Stimulating Factors
1996
1,4-Diazepane compounds as potent and selective CB2 agonists: Optimization of metabolic stability
2011
P1‐314: Pharmacological characterization of the new bace1 inhibitor bi 1181181
2015
Effect of granulocyte colony-stimulating factor treatment on ex vivo blood cytokine response in human volunteers
1995
Endotoxin-inducible granulocyte-mediated hepatocytotoxicity requires adhesion and serine protease release
1996
Testing of immunomodulatory properties in vitro.
1996
Über die Intensitätsverteilung von Spektrallinien im Pérot‐Fabry‐Interferometer
1953